本システムでは、JavaScriptを利用しています。JavaScriptを有効に設定してからご利用ください。

【参】六角形画像(IR Information)

H1

IR Library

パンくずリスト

ホーム > Kidswell Bio Corporation > IR Information > IR Library

コンテンツ

IR Library

★IR：カテゴリメニュー

IR Library

2022/04/04

Announcement of execution of share transfer agreement of the consolidated subsidiary and share purchase agreement with Metcela Inc., and change in the purpose of the 10th share acquisition rights due to this transaction (Extracted from Japanese version)
[PDF：291KB]
2022/03/24

Omega Bioscience Index has been released by OMEGA Investment Co., Ltd.
2022/03/17

Column about SHED (Stem cells from Human Exfoliated Deciduous teeth) has posted in the website of AMED iD3 Catalyst Unit.
2022/03/07

Company note 3Q update from OMEGA Investment [PDF：523KB]
2022/02/04

[Presentation] Financial Results for the Third Quarter of FY2021 [PDF：1670KB]
2022/02/04

Summary of Consolidated Financial Results for the Third Quarter of the Fiscal Year Ending March 31, 2022
[PDF：469KB]
2022/01/26

Announcement of business alliance agreement with Metcela Inc. for the regenerative medicine business [PDF：207KB]
2021/12/09

Announcement of the launch of Ranibizumab BS [PDF：120KB]
2021/11/25

Company note 2Q update from OMEGA Investment [PDF：274KB]
2021/11/05

Summary of Consolidated Financial Results for the Second Quarter of the Fiscal Year Ending March 31, 2021 [PDF：470KB]
2021/11/05

[Presentation] Financial Results for the Second Quarter of FY2021 [PDF：2373KB]
2021/10/21

Announcement of extraordinary income (gain on sale of investment securities) and revisions of the consolidated financial forecast for the FY 2021 [PDF：191KB]
2021/09/28

Company Research and Analysis Report from OMEGA Investment [PDF：4959KB]
2021/09/27

Announcement of Receiving Manufacturing and Sales Approval for biosimilar in the Ophthalmic Area in Japan [PDF：119KB]
2021/09/08

Announcement of collaborative research agreement with NanoCarrier Co., Ltd. for development of a designer cell as reinforced cell therapy utilizing SHED [PDF：251KB]
2021/08/12

[Presentation] Financial Results for the First Quarter of the Fiscal Year Ending March 31, 2022 [PDF：2274KB]
2021/08/12

Summary of Consolidated Financial Results for the First Quarter of the Fiscal Year Ending March 31, 2022 [PDF：456KB]
2021/05/17

Summary of Consolidated Financial Results for the Fiscal Year Ended March 31, 2021 [PDF：435KB]
2021/02/15

Summary of Our Mid-Term Strategic Plan from FY2021 to FY2025 [PDF：1678KB]
2021/01/22

Our mid-term strategic plan will be announced on Feb. 15.
2021/01/05

Interview video of Masaharu Tani, CEO, has been released at Sessa TV.
2020/11/09

Summary of Consolidated Financial Results for the Second Quarter of the Fiscal Year Ending March 31, 2021 [PDF：596KB]
2020/11/09

FY2020 2Q IR Meeting Information [PDF：3730KB]
2020/09/18

Announcement of Application for Approval of Manufacturing and Sales in Japan for biosimilar in the Ophthalmic Area [PDF：254KB]
2020/08/20

Announcement of Joint Research Agreement with Hokkaido University and Spinal Injuries Center for Non-Union Fractures [PDF：255KB]
2020/07/15

New business alliance with Dojin Group to accelerate research and development of regenerative medicine products by using SHED and expand SHED-related business [PDF：631KB]
2020/05/25

Summary of Consolidated Financial Results for the Fiscal Year Ended March 31, 2020 [PDF：480KB]
2020/05/25

FY2019 IR Meeting Information [PDF：1450KB]
2020/04/08

Announcement of completion of issuance of the 3rd series of convertible bond with stock acquisition rights and the 10th series of stock acquisition rights [PDF：336KB]
2020/03/23

[Presentation] Establishment of manufacturing process for the master cell bank and business alliance with Mochida Pharma, and Financing for driving JRM-001 [PDF：763KB]
2020/03/16

Announcement of Establishment of Manufacturing Process for Master Cell Bank Based on the Business Partnership with NIKON CORPORATION

[PDF：122KB]
2020/03/05

Announcement of Joint Research Agreement with Oita University for Peripheral Nerve Paralysis [PDF：176KB]
2020/03/05

Announcement of Joint Research Agreement with Nagoya University for Spinal Cord Injury [PDF：146KB]
2020/02/19

End of Observation Period for the Last Patient in Phase III Clinical Trial of Biosimilar Product for Ophthalmic Treatment in Japan Developed with Senju Pharmaceutical Co., Ltd.

[PDF：128KB]
2020/02/17

[Presentation] Announcement of Acquisition of Shares of Japan Regenerative Medicine Co., Ltd. [PDF：763KB]
2020/02/17

[Document] Announcement of Acquisition of Shares of Japan Regenerative Medicine Co., Ltd. [PDF：182KB]
2020/02/14

Announcement of Business Alliance Agreement with DOJIN GROUP Co, Ltd. for business development in regenerative medicine and healthcare area [PDF：124KB]
2020/02/05

FY2019 3Q IR Meeting Information [PDF：1828KB]
2020/02/05

Summary of Consolidated Financial Results for the Third Quarter of the Fiscal Year Ending March 31, 2020
[PDF：309KB]
2020/01/30

Signed alliance agreement with Eil for business development in regenerative medicine and healthcare area [PDF：115KB]
2020/01/22

Announcement of Joint Research Agreement for Cerebral Palsy with Three Institutes

[PDF：189KB]
2020/01/21

Announcement of Joint Research Agreement for New Antibodies with MabGenesis Inc.

[PDF：182KB]
2020/01/06

Announcement of Joint Development Agreement with Sapporo Medical University

[PDF：271KB]
2019/12/02

Announcement of Joint Development Agreement of Aflibercept Biosimilars with Kishi Kasei Co., Ltd.

[PDF：319KB]
2019/11/05

FY2019 2Q IR Meeting Information [PDF：1547KB]
2019/11/05

Summary of Consolidated Financial Results for the Second Quarter of the Fiscal Year Ending March 31, 2020 [PDF：341KB]
2019/11/05

Announcement of the Appointment of Scientific Advisor and Establishment of Scientific Advisory Board [PDF：243KB]
2019/11/05

Announcement of Academia-industry Collaboration with Showa University School of Medicine for a Development of Treatments in Cell Therapy Field using Stem Cells from Human Exfoliated Deciduous Teeth [PDF：138KB]
2019/10/16

Acquisition and Cancellation of the 6th Series of Stock Acquisition Rights (Private Placement) [PDF：130KB]
2019/10/07

Signed a Contract for Sale of Stem Cells from Human Exfoliated Deciduous Teeth between Kidswell Bio Corporation Co., Ltd.and Summit Pharmaceuticals International Corporation.

[PDF：151KB]

前へ
1
2
3
4
次へ